Altamira Therapeutics Ltd
NASDAQ:CYTO
Altamira Therapeutics Ltd
NASDAQ:CYTO
Price:
0.1198
USD
-60.07%
Market Closed
Market Cap:
$300k
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Altamira Therapeutics Ltd
Common Stock
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Altamira Therapeutics Ltd
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Altamira Therapeutics Ltd
NASDAQ:CYTO
|
Common Stock
CHf5.3k
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-67%
|
CAGR 10-Years
-52%
|
|
|
Novartis AG
SIX:NOVN
|
Common Stock
$766m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Common Stock
$2.9m
|
CAGR 3-Years
104%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Common Stock
CHf107m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-4%
|
|
|
O
|
Oculis Holding AG
NASDAQ:OCS
|
Common Stock
CHf587k
|
CAGR 3-Years
20%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Common Stock
$25m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
No Stocks Found
Altamira Therapeutics Ltd
Glance View
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders.
CYTO
Intrinsic Value
Not Available
See Also
What is Altamira Therapeutics Ltd's Common Stock?
Common Stock
5.3k
CHF
5.3k
CHF
Based on the financial report for Jun 30, 2024, Altamira Therapeutics Ltd's Common Stock amounts to 5.3k CHF.
What is Altamira Therapeutics Ltd's Common Stock growth rate?
Common Stock CAGR 10Y
-52%
-52%
Over the last year, the Common Stock growth was -100%. The average annual Common Stock growth rates for Altamira Therapeutics Ltd have been -66% over the past three years , -67% over the past five years , and -52% over the past ten years .
